2023 Global Biologics Sales exceeding US$ 300 bln for the first time

STUTTGART, Germany - March 9, 2024 - PRLog -- La Merie Publishing released the new report with sales data of recombinant biologics, biosimilars and novel biologic modalities. The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation and analysis of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2023. In addition, information about sales data of novel biologics, i.e. gene & cell therapy and RNA, is presented.

For the first time, global sales of branded originator antibodies and proteins increased by 3.6% % to US$ 300.3 bln compared with the previous year. Excluding sales of SARS-CoV-2 antibodies in 2022, the growth rate would have been 6.8% (sales of SARS-CoV-2 antibodies decreased from US$ 8.9 bln in 2022 to US$ 0.8 bln in 2023). Since 2012, global sales of innovator biologics have grown with a continuous annual growth rate of 8.44%.

Antibody sales represented 83.6% of total biologics sales in 2023. The strong growth of antibody sales was mainly driven by novel anti-inflammatory antibodies and immuno-oncology antibodies. Sales of anti-inflammatory antibodies (including anti-TNF antibodies) exceeded those of cancer antibodies by US$ 25 bln despite the strong decrease of sales of anti-TNF antibodies (-23.6% vs 2022).

Blockbuster status with 2023 sales exceeding US$ 1 bln was achieved by 69 recombinant antibody and protein products, with seven new entrants (most notably Roche's Vabysmo) and nine drop outs (SARS-CoV-2 antibodies and established proteins). Merck's anti-PD-1 Keytruda is the new no. 1 blockbuster biologic as Humira sales decreased by 32.6% vs 2022. Roche retains its leadership position among the top 30 pharmaceutical company with the highest sales of biologics (US$ 41.2 bln).

The report presents and analyzes sales and growth rates of antibody-drug conjugates (ADC) and of bispecific antibodies. The report includes information of biosimilar sales. Combined sales of novel biologic modalities for the first time have exceeded the threshold of US$ 10 bln (+27.6% vs 2022).

The report 2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics (https://lamerie.com/report/2023-sales-of-recombinant-ther...) can be acquired at La Merie Publishing's online store www.lamerie.com: https://lamerie.com/report/2023-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

SOURCE: La Merie Publishing